Fineline Cube

Follow:
14725 Articles
CompanyDrug

CSPC Pharma’s SYH2082 Wins NMPA Approval – Long‑Acting GLP‑1/GIP Dual‑Biased Agonist Enters Obesity Clinical Trials

CompanyDrug

Haihe Biopharma Wins Japan Approval for Risovalisib – First PI3Kα Inhibitor for Ovarian Clear Cell Carcinoma

Policy / Regulatory

China NHC Issues Medical Technology Evaluation Procedures – New Framework Triggers Restrictions or Bans on Controversial Clinical Practices

Medtronic Completes First Penditure Implant in Greater Bay Area – Recapturable LAA Closure System Leverages HK‑Macao Access Policy
CompanyMedical Device

Medtronic Completes First Penditure Implant in Greater Bay Area – Recapturable LAA Closure System Leverages HK‑Macao Access Policy

3SBio Wins NMPA Approval for SSS06 – Extended‑Half‑Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia
CompanyDrug

3SBio Wins NMPA Approval for SSS06 – Extended‑Half‑Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia

CompanyDrug

Alphamab Oncology Doses First Patient in JSKN016 Phase III – HER3/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer

CompanyDrug

Belief BioMed Secures Macao Approval for BBM‑H901 – China’s First Hemophilia B Gene Therapy Expands to Greater China with Takeda

Company

Sanofi Opens Chengdu Innovation Hub – 600‑Headcount China Operations Center to Drive R&D and Commercial Excellence

AstraZeneca to Build Radioligand Therapy Manufacturing Hub in Guangzhou – Actinium‑225 Facility Targets Asia‑Pacific Cancer Market
Company

AstraZeneca to Build Radioligand Therapy Manufacturing Hub in Guangzhou – Actinium‑225 Facility Targets Asia‑Pacific Cancer Market

Novo Nordisk Wins FDA Approval for Wegovy HD 7.2 mg – Higher‑Dose Semaglutide Delivers 21% Weight Loss in STEP UP Trial
CompanyDrug

Novo Nordisk Wins FDA Approval for Wegovy HD 7.2 mg – Higher‑Dose Semaglutide Delivers 21% Weight Loss in STEP UP Trial

CompanyDrug

Eli Lilly’s Retatrutide Delivers 2.0% A1C Reduction and 36.6 Lbs Weight Loss in Phase 3 Diabetes Trial – Triple‑Agonist Shows Best‑in‑Class Efficacy

Pfizer Reports Positive TALAPRO-3 Results – TALZENNA/XTANDI Combo Hits Primary Endpoint in HRR-Mutated Prostate Cancer
CompanyDrug

Pfizer Reports Positive TALAPRO-3 Results – TALZENNA/XTANDI Combo Hits Primary Endpoint in HRR-Mutated Prostate Cancer